Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-Current Deffered Revenue (2018 - 2025)

Dianthus Therapeutics (DNTH) has 6 years of Non-Current Deffered Revenue data on record, last reported at $6.1 million in Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue rose 848.12% year-over-year to $6.1 million; the TTM value through Sep 2025 reached $6.1 million, up 848.12%, while the annual FY2024 figure was $1.9 million, 159.24% up from the prior year.
  • Non-Current Deffered Revenue reached $6.1 million in Q3 2025 per DNTH's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $6.1 million in Q3 2025 and bottomed at $640000.0 in Q3 2024.
  • Average Non-Current Deffered Revenue over 4 years is $1.6 million, with a median of $768000.0 recorded in 2022.
  • Peak YoY movement for Non-Current Deffered Revenue: decreased 14.09% in 2024, then skyrocketed 848.12% in 2025.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $791000.0 in 2022, then dropped by 6.95% to $736000.0 in 2023, then skyrocketed by 159.24% to $1.9 million in 2024, then surged by 218.03% to $6.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $6.1 million in Q3 2025, $1.8 million in Q2 2025, and $1.9 million in Q1 2025.